Bookmark and Share
MLS002320446 (CID 44201929) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(8)
 
 
Inactive(385)
 
 
Inconclusive(5)
 
 
Unspecified(1)
 
 
Top Targets:
7tm 4(33)
 
 
 
RasGEF(4)
 
 
ABCC CFTR1(4)
 
 
CAP ED(4)
 
 
Troponin(4)
 
 
BioAssay Types:
Screening(283)
 
 
 
Confirmatory(101)
 
 
 
 
 
Literature(11)
 
 
BioActivity Types:
Potency(87)
 
 
 
 
 
IC50(7)
 
 
EC50(5)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 357    Data Row: 399   Total Pages: 20   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID85200807]
Potency 11.5821qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
2
[SID85200807]
Potency 20.5962qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
3
[SID85200807]
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504326, Type: screening]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
4
[SID85200807]
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH) [AID463082, Type: screening]platelet-activating factor acetylhydrolase precursor [Homo sapiens] [gi:270133071]
View
5
[SID85200807]
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504326, Type: screening]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
6
[SID85200807]
Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504904, Type: screening]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
7
[SID85200807]
Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504904, Type: screening]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
8
[SID85200807]
uHTS identification of inhibitors of NadD in a Colorimetric assay [AID602399, Type: screening]hypothetical protein SA1422 [Staphylococcus aureus subsp. aureus N315] [gi:15927174]
View
9
[SID85200807]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
10
[SID85200807]
Potency 12.5893qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent) [AID485341, Type: confirmatory]Chain A, Ampc Beta-Lactamase In Complex With 4-Methanesulfonylamino Benzoic Acid [gi:119389684]
View
11
[SID85200807]
EC50 18.931Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID588407, Type: confirmatory]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
12
[SID85200807]
EC50 18.931Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID588407, Type: confirmatory]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
13
[SID85200807]
Potency 35.4813qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS [AID624287, Type: confirmatory]Guanine nucleotide-binding protein G(s) subunit alpha isoforms short [gi:52000961]
View
14
[SID85200807]
EC50 92.48Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerization [AID588435, Type: confirmatory]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
15
[SID85200807]
EC50 92.48Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRD1 homodimerization [AID588411, Type: confirmatory]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
16
[SID85200807]
EC50 92.48Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput dose response assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) [AID588408, Type: confirmatory]5-hydroxytryptamine receptor 5A [Homo sapiens] [gi:13236497]
View
17
[SID85200807]
VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2 [AID686996, Type: screening]Caspase 6, apoptosis-related cysteine peptidase [Homo sapiens] [gi:13325293]
View
18
[SID85200807]
uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay [AID493012, Type: screening]DNA dC->dU-editing enzyme APOBEC-3G [Homo sapiens] [gi:13399304]
View
19
[SID85200807]
Potency qHTS for Inhibitors of Vif-A3G Interactions: qHTS [AID602310, Type: confirmatory]DNA dC->dU-editing enzyme APOBEC-3G [Homo sapiens] [gi:13399304]
View
20
[SID85200807]
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2) [AID686940, Type: screening]COUP transcription factor 2 isoform a [Homo sapiens] [gi:14149746]
View